Narata Roongtiva, Wangkaew Suparaporn, Kasitanon Nuntana, Louthrenoo Worawit
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University Hospital, Chiang Mai, Thailand.
Southeast Asian J Trop Med Public Health. 2007 May;38(3):528-36.
Infection, particularly pneumonia, is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). This study was performed to assess the prevalence, causative organisms, and outcomes of community-acquired pneumonia (CAP) in Thai SLE patients, and determine the predicting factors for death. A retrospective chart review of adult SLE patients, age >16 years, seen at the Division of Rheumatology, Chiang Mai University over an 18 year period was carried out. Cases diagnosed with CAP were selected for this study. Of 542 SLE patients, a total of 56 episodes of CAP occurred in 52 patients. Their mean age +/- SD and duration of SLE were 37.98 +/- 11.48 years and 34.99 +/- 54.53 months, respectively. Thirty-three CAP cases (58.9%) occurred within the first year of diagnosis with SLE. The causative organisms identifiable in 40 patients (71.5%) were Mycobacterium tuberculosis in 12, Nocardia spp in 6, Aspergillus spp in 5, Staphylococcus aureus in 3, Pneumocystis carinii, Haemophilus influenzae, Escherichia coli, and Pseudomonas aeruginosa in 2 each, and Acinetobactor baumanii, Burkholderia pseudomallei, and Strongyloides stercoralis in 1 each. The remaining 3 patients had mixed bacterial infection. The overall mortality rate was 26.8%. Use of high dose prednisolone (> or =15 mg/day), and ventilator support were significantly associated with death.
感染,尤其是肺炎,是系统性红斑狼疮(SLE)患者发病和死亡的主要原因。本研究旨在评估泰国SLE患者社区获得性肺炎(CAP)的患病率、致病微生物及转归,并确定死亡的预测因素。对清迈大学风湿病科18年间诊治的年龄>16岁的成年SLE患者进行了回顾性病历审查。选取诊断为CAP的病例进行本研究。在542例SLE患者中,52例患者共发生56次CAP发作。他们的平均年龄±标准差和SLE病程分别为37.98±11.48岁和34.99±54.53个月。33例(58.9%)CAP病例发生在SLE诊断后的第一年内。40例(71.5%)患者可识别的致病微生物为:结核分枝杆菌12例,诺卡菌属6例,曲霉属5例,金黄色葡萄球菌3例,卡氏肺孢子虫、流感嗜血杆菌、大肠埃希菌和铜绿假单胞菌各2例,鲍曼不动杆菌、类鼻疽伯克霍尔德菌和粪类圆线虫各1例。其余3例为混合细菌感染。总死亡率为26.8%。使用高剂量泼尼松龙(≥15mg/天)和呼吸机支持与死亡显著相关。